GLP-1 Insurance Coverage Checker 2026 — Which Drug Your Plan Is Most Likely to Cover
Answer five questions to match your situation to the right GLP-1 and cost path — then estimate how likely your plan is to cover it. Uses 2026 commercial and Medicare Part D formulary patterns.
Updated April 2026
Medical disclaimer: This tool is for informational purposes. Not medical advice. Consult your healthcare provider before starting, stopping, or changing any medication. Drug prices, savings cards, and coverage policies change frequently — verify current pricing directly with the manufacturer or your pharmacy.
Which GLP-1 is right for you?
Five questions, one recommendation. The quiz applies hard clinical rules (cardiovascular label, OSA label, etc.) and soft weights to route you to the drug and access path most consistent with your situation.
Five questions. We'll match you to the GLP-1 and cost path most consistent with your answers. No data leaves your browser.
Answer every question to continue.
Coverage-likelihood estimator
Plug in your plan type, BMI, and diagnosis. The tool estimates approval likelihood using 2026 commercial, Marketplace, Medicare, and Medicaid formulary patterns.
Your inputs
Results
Coverage likelihood
85%
Good odds
Medicare is specifically prohibited from covering drugs for weight loss. T2D diagnosis is the most reliable path to coverage.
How 2026 coverage actually works
The GLP-1 coverage landscape has split into four clean buckets in 2026, and your real answer almost always falls into one of them.
Commercial plan covers AOMs with prior auth. You can get Wegovy or Zepbound for a $25–$100 copay after clearing a BMI-and-comorbidity PA. About 35–40% of large employer plans sit here. Your lever: the prior-auth guide.
Commercial plan covers T2D GLP-1s only. You can get Ozempic or Mounjaro for T2D but not Wegovy/Zepbound for weight loss. About 90% of commercial plans cover T2D GLP-1s. If you have T2D, this is a solved problem.
Medicare Part D via CV or OSA indication. Wegovy is now covered for patients with established CV disease (SELECT). Zepbound is covered for OSA in obesity (SURMOUNT-OSA). Medicare still does not cover GLP-1s for obesity alone.
No coverage. LillyDirect sells Zepbound vials at $349 (2.5 mg) or $499 (5–15 mg). NovoCare sells Wegovy vials at $499 for 1.7 mg and 2.4 mg. These are the cheapest reliable paths without coverage in 2026.
What a strong prior-auth packet looks like in 2026
Most denials fail on documentation, not clinical fit. A strong packet almost always contains: current BMI measured in-visit (not self-reported, not a year old), at least one obesity-qualifying comorbidity coded with its ICD-10 (E11.9 for T2D, I10 for HTN, E78.5 for HLD, G47.33 for OSA, K75.81 for NAFLD, I25.10 for CVD), documentation of 3–6 months of structured weight-loss attempts with dates and method, contraindication screen (MTC/MEN2 family history, pregnancy status), and trial-aligned language (“appropriate candidate per STEP 1 / SURMOUNT-1 eligibility”).
The most common coverage mistakes
Searching the wrong brand. Ozempic and Wegovy are both semaglutide but covered under different formulary categories. Always search the AOM category for weight-loss coverage.
Accepting the first denial. Peer-to-peer reviews overturn a meaningful share of denials. Most patients never request one.
Ignoring the OSA path for Zepbound. If you have obesity and AHI ≥ 15 on a home sleep study, the SURMOUNT-OSA indication is often a stronger PA path than AOM alone.
Skipping the manufacturer savings card. $25/month copays are standard on Wegovy and Zepbound with the savings card on commercial plans.
Assuming Medicare doesn’t cover GLP-1s. Wegovy and Zepbound have post-SELECT and post-SURMOUNT-OSA indications that Part D plans now cover.
Employer self-insured ERISA plans: the escalation lever most patients miss
If your plan is self-insured (most large employers), your employer — not the carrier — sets coverage. An HR benefits manager can approve a carve-out even when the formulary excludes AOMs. This rarely happens by default, but it happens when patients write a respectful, data-driven request referencing SELECT cardiovascular outcomes or SURMOUNT-OSA. A standard template: chronic disease status, treatment plan, expected ROI on reduced cardiovascular/endocrine claims. Your HR team may route you to a benefits committee; that committee sometimes updates plan design at the next renewal.
How do I find out if my plan covers Wegovy or Zepbound?
Three ways. (1) Log into your member portal and search the formulary for 'semaglutide 2.4 mg' or 'tirzepatide for weight management' — don't just search 'Wegovy' or 'Zepbound' (brand names sometimes hit T2D entries). (2) Call the number on your card and ask whether your plan covers anti-obesity medications (AOMs) and what prior-auth criteria apply. (3) Ask your prescriber's office to run a pharmacy-benefit check via CoverMyMeds before the visit ends — most systems return a copay estimate inside 60 seconds.
What percentage of commercial plans cover GLP-1s for weight loss in 2026?
KFF's 2024 employer survey found about 18% of large employers covered GLP-1s for weight loss. That rose to ~34% by Q4 2025, and estimates for 2026 land in the 38–44% range as more state insurance commissioners pressure carriers post-SELECT and SURMOUNT-OSA. Coverage for T2D indications (Ozempic, Mounjaro) is much higher — near 90% of commercial plans and most Medicaid lines.
Does Medicare cover Wegovy or Zepbound?
Medicare Part D traditionally excluded obesity-only drugs, but SELECT cardiovascular approval opened a path: Wegovy is now covered on Medicare for patients with established cardiovascular disease and overweight/obesity. SURMOUNT-OSA opened a similar path for Zepbound in patients with obstructive sleep apnea and obesity. Medicare does not cover GLP-1s for weight loss alone. Always check your specific Part D plan's formulary.
What's the difference between Ozempic and Wegovy from an insurance standpoint?
Pharmacologically they're the same drug (semaglutide) at different top doses (1.0/2.0 mg vs 2.4 mg). Insurance-wise they're entirely different animals. Ozempic is T2D-indicated — covered by ~90% of commercial plans with a standard T2D prior auth. Wegovy is AOM-indicated — covered by ~35–40% of commercial plans with a BMI-based prior auth that requires documented prior weight-loss attempts. Do not ask for Ozempic off-label for weight loss; ask for the appropriate drug for your diagnosis.
My prior auth was denied. What's my best next step?
Request a peer-to-peer review within 5 business days — your prescriber calls the plan's medical director to discuss the case. Peer-to-peers reverse a surprising share of denials. If that fails, file a formal internal appeal (every plan must allow one per ACA) within 60 days, then an external review via your state's independent reviewer. While the appeal is running, use LillyDirect ($349–$499) or NovoCare ($499) vial self-pay to avoid losing weight-loss momentum. The prior-auth guide has the full sequence.
What does the quiz use to match me to a drug?
The quiz weighs your primary clinical goal (weight, T2D, CV risk, OSA, PCOS), your coverage status, your GI sensitivity, your weight-loss ambition, and your cost ceiling. Hard rules override weights: cardiovascular-goal respondents are routed to Wegovy (only drug with SELECT indication); OSA-goal respondents are routed to Zepbound (only drug with SURMOUNT-OSA indication); uncovered + under-$500 budget is routed to LillyDirect or NovoCare vial self-pay.
Is my quiz data stored anywhere?
Your answers and result save only in this browser's localStorage so you can come back to them. Nothing is sent to a server. Clear your browser data to wipe.
What if the quiz says one drug but my prescriber suggests another?
Your prescriber wins. The quiz captures public evidence and access patterns; your clinician knows your chart. If the recommendations conflict, ask why — most of the time there's a specific reason (interaction, contraindication, local formulary quirk). Bring the quiz summary and the prior-auth checklist to the visit as a conversation starter, not a verdict.
Digital Dashboard Hub
Track your GLP-1 progress, weight loss, and health metrics
DDH has 54 health and wellness trackers — weight loss logs, BMI history, symptom tracking, and habit tools — built for your GLP-1 journey. Free 14-day trial.